This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 12/12/2008
SPC Oily Phenol Injection BP (UCB Pharma Ltd)


Go to top of the page
1. Name of the medicinal product

Oily Phenol Injection BP 5% w/v


Go to top of the page
2. Qualitative and quantitative composition

Phenol BP 5.00 % w/v


Go to top of the page
3. Pharmaceutical form

Sterile solution intended for parenteral use


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Scleropathy of haemorrhoids


Go to top of the page
4.2 Posology and method of administration

Injected into sub-mucosal layer at the base of the haemorrhoid

ADULTS

2-3 ml of oily phenol injection into the sub-mucosal layer at the base of the pile; Several injections may be given at different sites but not more than a total volume of 10 ml should be used at any one time.

CHILDREN

Use of this product is not advised

ELDERLY

No alternative dosage schedules have been suggested.


Go to top of the page
4.3 Contraindications

Oily Phenol Injection, BP is contraindicated in patients who are hypersensitive to phenol, nuts and in particular almond oil or any component of the product. It should not be used over large areas, since sufficient amounts may be absorbed to give rise to toxic symptoms. Oily Phenol Injection, BP is also contraindicated in neonates and children.


Go to top of the page
4.4 Special warnings and precautions for use

For submucosal injection only. Not for intrathecal use. Complications of therapy can include local ulceration and sterile abscess formation. These complications may be serious following a misplaced injection (eg prostatic abscess). Care in choosing the correct site of injection is mandatory.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated


Go to top of the page
4.6 Pregnancy and lactation

Safety in pregnancy has not been established. The effects on the foetus are unknown, therefore Oily Phenol is not recommended for use during pregnancy.

It is not known whether Oily Phenol is excreted in breast milk. Since safety in infants has not been established, Oily Phenol injection is not recommended for use whilst breast-feeding.


Go to top of the page
4.7 Effects on ability to drive and use machines

Effects of phenol oily injection are not likely to affect the patient's ability to drive and use machinery.


Go to top of the page
4.8 Undesirable effects

General disorders and administration site conditions:

Pyrexia

Pain

Discomfort

Ulcer

Immune system disorders:

Hypersensitivity

Nervous system disorders:

Dizziness

Hepatobiliary disorders:

Hepatitis

Infections and infestations:

Abscess

Prostatic abscess

Necrotizing fasciitis

Retroperitoneal sepsis

Renal and urinary disorders:

Dysuria

Urinary incontinence

Reproductive system and breast disorders:

Impotence


Go to top of the page
4.9 Overdose

Symptoms:

The symptoms of overdosage after submucosal injection of Oily Phenol are not known, but are likely to be similar to symptoms observed after excessive exposure to phenol in other preparations. Absorption of phenol after application of dilute phenol solutions to extensive wounds has resulted in abdominal pains, dizziness, methaemoglobinaemia, haemoglobinurea, cyanosis, cardiac arrhythmias, ECG abnormalities, and may result in respiratory failure, circulatory failure, coma and death.

Treatment:

There is no specific antidote for acute phenol overdose. Treatment of overdose is symptomatic and supportive.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Oily phenol injection acts as an analgesic and thrombotic agent by numbimg the sensory nerve endings and precipitating proteins.


Go to top of the page
5.2 Pharmacokinetic properties

Phenol is absorbed from the gastro-intestinal tract and through skin and mucous membranes. It is metabolised to phenylglucoronide and phenylsulphate and small amounts are oxidised to catechol and quinol which are mainly conjugated. The metabolites are excreted in the urine; on oxidation to quinones they may tint the urine green.


Go to top of the page
5.3 Preclinical safety data

No data available


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Almond oil


Go to top of the page
6.2 Incompatibilities

Incompatible with alkaline salts, acetanilide, phenazone, piperazine, quinine salts, phenacetin and iron salts. Phenol coagulates albumin and gelatinises collodion.


Go to top of the page
6.3 Shelf life

3 years


Go to top of the page
6.4 Special precautions for storage

Store below 25 ° C


Go to top of the page
6.5 Nature and contents of container

5 ml neutral glass (type 1) ampoules supplied in cartons of 10


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated


Go to top of the page
7. Marketing authorisation holder

UCB Pharma Limited

208 Bath Road

Slough

Berkshire

SL1 3WE

UK


Go to top of the page
8. Marketing authorisation number(s)

PL 0039/5690R


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

20 March 1987 / 15 October 1997


Go to top of the page
10. Date of revision of the text

23rd September 2008



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/4849/SPC/


Active Ingredients/Generics